BioSpace News Archive

Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA) today announced that the U.S. Food and Drug Administration (FDA) has cleared Biomea’s IND application to begin a Phase I/Ib trial of BMF-219, a selective, covalent menin inhibitor in patients with unresectable, locally advanced, or metastatic NSCLC, CRC, and PDAC with an activating KRAS mutation.

Altasciences hired two expert advisors to support its strategic growth in Europe, while its preclinical team continues to expand with the addition of two key employees.

More than two years after the COVID-19 pandemic began, diagnoses of breast and prostate cancer, two of the nation’s leading causes of cancer death, continue to lag behind pre-pandemic levels, according to a nationally representative Quest Diagnostics Health Trends® study by Quest Diagnostics, the world’s leading provider of diagnostic information services.

Bioretec Ltd, a pioneer in bioresorbable orthopedic implants, continues to discuss the company’s RemeOs™ trauma screw market authorization with the U.S. Food and Drug Administration.

A new study recently published in the journal Annals of Internal Medicine, written by The Feinstein Institutes for Medical Research’s Karina Davidson, PhD, reviews preventative lung cancer screening guidelines and outlines hurdles health systems and clinicians still need to overcome to make prevention more effective – including the need for follow-up care.

Sintetica, a Swiss pharmaceutical company headquartered in Mendrisio specializing in injectables in the field of pain therapy, has taken another important and significant step in its 100-year growth strategy.

Sienna Senior Living Inc. (“Sienna” or the “Company”) (TSX: SIA) announced that it will report its 2022 third quarter results after market close on Wednesday, November 9, 2022.

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

electroCore, Inc. (the “Company”) (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today provided select unaudited preliminary financial guidance for the third quarter of 2022.

Ampio Pharmaceuticals, Inc., released the following letter to stockholders from its Chairman, Kevin Buchi, and Chief Executive Officer, Mike Martino.